SB-590885

triarylimidazole derivative bearing a 2,3-dihydro-1H-inden-1-one oxime substituent , a potent and extremely selective inhibitor of B-Raf kinase; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Adams, Jerry L: 1 article (12/2006)
2.	Batorsky, Roberta S: 1 article (12/2006)
3.	Chau, David: 1 article (12/2006)
4.	Contractor, Rooja G: 1 article (12/2006)
5.	Do, Hieu T: 1 article (12/2006)
6.	Herlyn, Meenhard: 1 article (12/2006)
7.	Ho, Maureen L: 1 article (12/2006)
8.	Huang, Pearl S: 1 article (12/2006)
9.	Hugger, Erin: 1 article (12/2006)
10.	Karreth, Florian: 1 article (12/2006)

Related Diseases

1.

Neoplasms (Cancer) 12/01/2006 - "Malignant cells expressing oncogenic B-Raf show selective inhibition of mitogen-activated protein kinase activation, proliferation, transformation, and tumorigenicity when exposed to SB-590885, whereas other cancer cell lines and normal cells display variable sensitivities or resistance to similar treatment. " 12/01/2006 - "Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885."

Related Drugs and Biologics

1.	Mitogen-Activated Protein Kinases
2.	Phosphotransferases (Kinase)